Enzo Biochem Inc (ENZ)

5.11
0.19 3.90
NYSE : Health Care
Prev Close 4.92
Open 4.93
Day Low/High 4.88 / 5.18
52 Wk Low/High 3.12 / 7.00
Volume 104.80K
Avg Volume 188.40K
Exchange NYSE
Shares Outstanding 46.27M
Market Cap 233.18M
EPS -0.10
P/E Ratio 12.92
Div & Yield N.A. (N.A)

Latest News

Oversold Conditions For Enzo Biochem (ENZ)

Oversold Conditions For Enzo Biochem (ENZ)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Short Interest Decreases By 30.7% For ENZ

Short Interest Decreases By 30.7% For ENZ

The most recent short interest data has been released for the 06/30/2016 settlement date, which shows a 661,112 share decrease in total short interest for Enzo Biochem, Inc. , to 1,494,651, a decrease of 30.67% since 06/15/2015.

Enzo Biochem's Life Sciences Unit Reaches $21 Million Patent Infringement Settlement In Delaware With Illumina, Inc.

Enzo Biochem's Life Sciences Unit Reaches $21 Million Patent Infringement Settlement In Delaware With Illumina, Inc.

Enzo Biochem, Inc. (NYSE:ENZ) today announced that its subsidiary, Enzo Life Sciences, Inc.

Enzo Biochem Added To Russell 2000, Russell 3000 And Russell Global Indexes

Enzo Biochem Added To Russell 2000, Russell 3000 And Russell Global Indexes

Enzo Biochem (NYSE:ENZ) announced that it has been included in the broad-market Russell 3000® Index, Russell 2000® Index and Russell Global Index, which reconstituted after the market closed on Friday, June 24 th.

These Undervalued Stocks Are Unfairly Overlooked

These Undervalued Stocks Are Unfairly Overlooked

David Marcus, portfolio manager for the Evermore Global Value Fund, is trying to change that perception.

Enzo Biochem Reports Fiscal Third Quarter Results

Enzo Biochem Reports Fiscal Third Quarter Results

Enzo Biochem, Inc. (NYSE:ENZ) today reported results for the third fiscal quarter and nine months ended April 30, 2016, with strong across the board advances.

Enzo Biochem Announces New York State Approval Of New Women's Test Based On Proprietary Technology

Enzo Biochem Announces New York State Approval Of New Women's Test Based On Proprietary Technology

Enzo Biochem, Inc. (NYSE:ENZ) today announced that the New York State Department of Health has granted conditional approval for use of Enzo Clinical Labs' AmpiProbe Candidiasis™ assay, the Company's second test aimed...

Enzo Biochem Schedules Teleconference To Discuss Third Quarter 2016 Results Wednesday, June 8, 2016 At 8:30 AM E.T.

Enzo Biochem Schedules Teleconference To Discuss Third Quarter 2016 Results Wednesday, June 8, 2016 At 8:30 AM E.T.

Enzo Biochem, Inc. (NYSE:ENZ), will hold a conference call to discuss fiscal 2016 third quarter results, Wednesday, June 8, 2016, at 8:30 AM E.

Enzo Biochem's Life Sciences Unit Reaches $35 Million Patent Infringement Settlement In Delaware With Life Technologies Corporation

Enzo Biochem's Life Sciences Unit Reaches $35 Million Patent Infringement Settlement In Delaware With Life Technologies Corporation

Enzo Biochem, Inc. (NYSE:ENZ) today announced that its subsidiary, Enzo Life Sciences, Inc.

Enzo Biochem Submits AmpiProbe Based Assay Targeted At Women's Health For Approval To New York State Department Of Health

Enzo Biochem Submits AmpiProbe Based Assay Targeted At Women's Health For Approval To New York State Department Of Health

Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has submitted to the New York State Department of Health a validation package for its newest AmpiProbe™ based assay -- designed to identify the presence of the...

Enzo Biochem Reports Increased Fiscal Second Quarter Results

Enzo Biochem Reports Increased Fiscal Second Quarter Results

Enzo Biochem, Inc. (NYSE:ENZ) today reported results for the second fiscal quarter and fiscal first half ended January 31, 2016, led by strong gains at Enzo Clinical Labs reflecting increased molecular diagnostic testing...

Enzo Biochem Schedules Teleconference To Discuss Second Quarter 2016 Results Thursday, March 10, 2016 At 8:30 AM E.T.

Enzo Biochem Schedules Teleconference To Discuss Second Quarter 2016 Results Thursday, March 10, 2016 At 8:30 AM E.T.

Enzo Biochem, Inc. (NYSE:ENZ), will hold a conference call to discuss fiscal 2016 second quarter results, Thursday, March 10, 2016, at 8:30 AM E.

Enzo Biochem Collects $7 Million From Court Approved Escrow Fund Closings

Enzo Biochem Collects $7 Million From Court Approved Escrow Fund Closings

Enzo Biochem, Inc. (NYSE:ENZ) and wholly-owned Enzo Life Sciences, Inc.

Enzo Biochem Updates Corporate Developments At Annual Shareholders Meeting

Enzo Biochem Updates Corporate Developments At Annual Shareholders Meeting

Enzo Biochem Inc. (NYSE:ENZ) announced the results of its Annual Shareholders Meeting today and updated shareholders on its businesses.

Enzo Biochem Reaches $9 Million Patent Infringement Settlement With Agilent Technologies, Inc.

Enzo Biochem Reaches $9 Million Patent Infringement Settlement With Agilent Technologies, Inc.

Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has reached and finalized a settlement with Agilent Technologies, Inc.

Enzo Comments On Lone Star's Decision To Withdraw Its Proxy Contest

Enzo Comments On Lone Star's Decision To Withdraw Its Proxy Contest

Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo") today issued the following statement regarding Lone Star's decision to withdraw its proxy contest: "Lone Star Value has issued a statement indicating that it has determined to...

Lone Star Value Issues Statement To Fellow Enzo Shareholders

Lone Star Value Issues Statement To Fellow Enzo Shareholders

Responds to Flaws in ISS Report and Enzo's False Allegations

ISS Endorses Enzo's Nominees For Company's Board Of Directors

ISS Endorses Enzo's Nominees For Company's Board Of Directors

Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo") today announced that Institutional Shareholder Services (ISS), a leading independent proxy voting advisory firm, has recommended that Enzo shareholders vote on the WHITE proxy card...

Glass Lewis Supports Enzo Nominees For Company's Board Of Directors

Glass Lewis Supports Enzo Nominees For Company's Board Of Directors

Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo") today announced that Glass Lewis, a leading independent proxy voting advisory firm, has recommended that Enzo shareholders vote on the WHITE proxy card to elect both of Enzo's two...

Enzo Biochem Issues Open Letter To Shareholders

Enzo Biochem Issues Open Letter To Shareholders

Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo") has issued the below letter to shareholders: December 22, 2015 Dear Fellow Shareholder, Enzo Biochem, Inc.

Analysts' Actions -- CVS Health, Micron, Qualcomm, Pandora and More

Analysts' Actions -- CVS Health, Micron, Qualcomm, Pandora and More

Here are Thursday's top research calls, including upgrades for Micron, Pandora and Qualcomm, and a downgrade for CVS Health.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BLOX, ENZ, MAGS Downgrades: AETI, ARCX, MMI, PHX, POST, SPLS Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Enzo Biochem Reports Strong First Quarter

Enzo Biochem Reports Strong First Quarter

Enzo Biochem Inc. (NYSE:ENZ) today reported another period of strong results for the first fiscal quarter ended October 31, 2015.

Enzo Biochem Schedules Teleconference To Discuss First Quarter 2016 Results Tuesday, December 8, 2015 At 8:30 AM E.T.

Enzo Biochem Schedules Teleconference To Discuss First Quarter 2016 Results Tuesday, December 8, 2015 At 8:30 AM E.T.

Enzo Biochem, Inc. (NYSE:ENZ), will hold a conference call to discuss fiscal 2016 first quarter results, Tuesday, December 8, 2015, at 8:30 AM E.

Enzo Biochem Releases New Investor Presentation On Corporate Strategy

Enzo Biochem Releases New Investor Presentation On Corporate Strategy

Enzo Biochem, Inc. (NYSE:ENZ) today released a new investor presentation that, in light of recently announced approval for the Company's HCV viral load testing by the New York State Department of Health, centers on an...

Enzo Biochem Announces New York State Approval Of Its First Assay Based On AmpiProbeTM Platform Aimed At Providing Affordable Molecular Diagnostics In Light Of Reimbursement Pressure

Enzo Biochem Announces New York State Approval Of Its First Assay Based On AmpiProbeTM Platform Aimed At Providing Affordable Molecular Diagnostics In Light Of Reimbursement Pressure

Enzo Biochem, Inc. (NYSE:ENZ) today announced that the New York State Department of Health has granted approval of Enzo Clinical Labs' AmpiProbe-HCV ™ assay for the quantitative detection of Hepatitis C virus,...

Enzo Biochem Demonstrates Greater Sensitivity Of Its AmpiProbe™ Platform For Molecular Diagnostics

Enzo Biochem Demonstrates Greater Sensitivity Of Its AmpiProbe™ Platform For Molecular Diagnostics

Enzo Biochem, Inc. (NYSE: ENZ) today announced it had demonstrated new thresholds of sensitivity and breadth for its assay for the measurement of Hepatitis C virus (HCV) viral load.

Enzo Biochem Reaches $10 Million Patent Infringement Settlement With Affymetrix, Inc.

Enzo Biochem Reaches $10 Million Patent Infringement Settlement With Affymetrix, Inc.

Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has reached and finalized a settlement with Affymetrix, Inc.